AIM ImmunoTech Plunges 51.11% Amid Market Volatility

AIM ImmunoTech's stock plummeted by 51.11% in pre-market trading on July 29, 2025, marking a significant downturn for the biotechnology company.

AIM ImmunoTech's recent stock surge was driven by positive data from the DURIPANC trial, which demonstrated superior survival and safety outcomes in metastatic pancreatic cancer patients. This trial data has been a key factor in the company's recent performance, highlighting the potential of its therapeutic approaches in treating aggressive forms of cancer.

However, the company's stock has also faced volatility due to broader market conditions and investor sentiment. The biotechnology sector as a whole has seen fluctuations, with some companies experiencing setbacks while others continue to make strides in clinical trials and regulatory approvals. AIM ImmunoTech's performance reflects the dynamic nature of the biotech industry, where breakthroughs and challenges often coexist.